GU part 2 Flashcards
Components of ED
Impotence
Peyronie’s dz
Trauma
Ejaculatory dysfunction (EjD)
When does ED increase?
Age
Smoking
CVD
Does not correlate with testosterone levels
Mechanism of erection
Psychologic or tactile sexual stimulation initiates pathway
Parasympathetic fibers from sacrospinal cord levels S2-S4 join pelvic plexus
Nerve signals carry through pelvic plexus into cavernous nerves of penile corpora cavernosa
Chemical reaction of erection
Sexual stimulation that releases nitric oxide (NO) by cavernous nerves into neuromuscular junction
NO activates enzyme guanylyl cyclase
Guanylyl cyclase converts GTP into cGMP
cGMP activates protein kinase G enzyme
Protein kinase G activates protein kinase but decreased intracellular calcium
Decreased smooth muscle calcium causes neuromuscular relaxation and cavernosal artery dilation
Increased blood flow and penile erection occurs
Venous outflow mediates erectile detumescence
Causes of erectile dysfunction
Neuromuscular junction d/os Endocrine d/os Vascular dz Neurogenic erectile dysfunction Medication-induced erectile dysfunction
Neuromuscular junction disorders that cause ED
Examples- MS, Parkinson’s dz
>60% of pts with ED respond to PDE-5 inhibition
Low dose medical tx successful in most cases
Endocrine disorders for ED- pathology
Testosterone metabolically inactive
Dihydrotestosterone metabolically active
Testosterone plays permissive role in ED
Testosterone affects libido
Testosterone replacement corrects ED in pts with very low serum testosterone
Testosterone replacement rarely helps ED if only mildly low
S/sx of ED caused by endocrine disorders
Weakness Fatigue Lack of motivation Lack of libido Weight gain
Testosterone preparations
Depo-testosterone injections 300 mg IM q 2 wks Aveed 750 mg IM week 0, 4, then every 10 wks AndroGel 1.62% 5 grams to skin q AM Fortesia 40 mg (4 pumps) daily Axiron 60 mg (2 pumps) daily Testim 5 gms (one pack) to skin q AM Androderm patch to skin q day Compounded topical testosterone
DM and ED
MC endocrine d/o affecting erectile function
Causes atherosclerotic small vessel vascular dz
Also causes loss of function to autonomic nerves
DM also causes dysfunction of neuromuscular junction via arterial and smooth muscle of penile corpora cavernosa
Endocrine disorders that cause ED
Hypothyroidism
Hyperthyroidism
Adrenal dysfunction
Vascular dz and ED
ASCVD results in mechanical obstruction of vascular lumen
Endothelial dysfunction in ASCVD interrupts neural control of vascular smooth muscle function
Results in decreased corpora cavernosal arterial pressure
Treatable with PDE-5 inhibitors or vasoactive intracorporal injection
Venoocclusive dz- venous leak- initial rigidity, but quick detumescence before ejaculation
Neurogenic ED
Spinal cord injury or peripheral nerve injury may prevent initiation of erectile cascade
Spinal cord injury ED tx
Respond to tactile sensation, but require medical therapy to maintain erection
Psychogenic ED
Temporal lobe involved
Pelvic fx and ED
Causes pudendal nerve damage and ED
Medication-induced ED
Substitution within class of meds rarely helps ED Proceed directly to tx of ED
Options for medical tx of ED
Oral PDE-5 inhibitors
Intraurethral alprostadil
Intracavernous vasoactive injections
Yohimbine
What are the PDE-5 inhibitors?
Cialis (tadalafil) Levitra (vardenafil) Staxin (vardenafil) Viagra (sildenafil) Stendra (avanafil)
MOA of PDE-5 inhibitors
Inhibits PDE-5 breakdown of cGMP
Increases NO and cGMP levels resulting in maintained erections
Sexual stimulation necessary for vasoactive pathways to work with PDE-5 inhibitors
CIs and caution for PDE-5 inhibitors
Generally first line therapy
CIed if used with nitrates (hypotension)
Caution when used with alpha-blockers (4-hr separation)
Benefits of PDE-5 inhibitor therapy
Can be taken orally
Well-tolerated by most pts
High success rate when used appropriately
Results in natural erection
Vacuum constriction device for ED (Response II, VET-CO)
Vacuum plastic tube around penis Rubber constrictive device at base of penis May be used with PDE-5 inhibitors Safe Often preferred by elderly No longer covered by Medicare
Soma therapy- ED
Peyronie's correction therapy Prostatectomy recovery therapy Drug enhancement therapy Penile implant enhancement therapy Concomitant use with other therapies
Pharmacologic injection therapy- ED
Vasoactive agents injected into corpus cavernosa
Agents include PGE1, papaverine, phentolamine
PGE1 used as monotherapy
Papaverine and phentolamine is double mix
PGE1, papaverine, phentolamine is triple mix
Complications of pharmacologic injection therapy for ED
Priapism
Penile curvature
Efficacy 90%
60% of pts stop using within 1 yr
Intraurethral drug therapy for ED
PGE1 intraurethral pallet
Less effective than intracavernous injection
Useful in pts who must be on nitrates
Painful urethral irritation
Penile prosthesis for ED
Semi-rigid always firm
Inflatable three piece prosthesis more natural
90% partner and pt satisfaction rate
Most effective long-term tx for ED
Clinical problems associated with androgen deficiency
Muscle wasting Decreased body hair Decreased hematopoiesis Increased fxs Increased fat Poor concentration ability Osteoporosis Sexual dysfunction